Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.

Journal article

Aksöz M. et al, (2024), Sci Immunol, 9

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Journal article

Jakobsen NA. et al, (2024), Cell Stem Cell

Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging

Preprint

Jakobsen NA. et al, (2023)

Identification and Age-dependent Increase of Platelet Biased Human Hematopoietic Stem Cells

Preprint

Aksöz M. et al, (2022)

Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation

Conference paper

Jakobsen NA. et al, (2022), BLOOD, 140, 2227 - 2228

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies.

Conference paper

Lachowiez CA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39

Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.

Journal article

Juban G. et al, (2021), Haematologica, 106, 1106 - 1119

Mechanisms of Response and Resistance to AML Therapies.

Journal article

Stoilova B. et al, (2020), Clin Lymphoma Myeloma Leuk, 20 Suppl 1

Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax plus /- azacitidine in IDH1-mutated hematologic malignancies.

Conference paper

Lachowiez CA. et al, (2020), JOURNAL OF CLINICAL ONCOLOGY, 38

C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor.

Journal article

Di Genua C. et al, (2020), Cancer Cell, 37, 690 - 704.e8

OncogenicGata1causes stage-specific megakaryocyte differentiation delay

Journal article

Juban G. et al, (2019), Haematologica: the hematology journal

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Journal article

Labuhn M. et al, (2019), Cancer Cell, 36

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Journal article

Labuhn M. et al, (2019), Cancer Cell, 36, 123 - 138.e10

The Inflammasome: More Than a Protective Innate Immune Mechanism.

Journal article

Stoilova B. and Vyas P., (2019), Immunity, 51, 3 - 5

A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.

Journal article

Roos-Weil D. et al, (2019), Cancer Discov, 9, 796 - 811

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Journal article

Quek L. et al, (2018), Nat Med, 24, 1167 - 1177

Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.

Journal article

Karamitros D. et al, (2018), Nat Immunol, 19, 85 - 97

A Novel Model of Human Hemopoiesis Based on Single Cell Functional and Transcriptional Analysis of Lympho-Myeloid Progenitors

Conference paper

Stoilova B. et al, (2017), BLOOD, 130

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Conference paper

Quek L. et al, (2017), BLOOD, 130

Impact of Mutant Haemopoietic Transcription Factor GATA1s on Haemopoiesis

Conference paper

Vyas P. et al, (2017), BLOOD, 130

Load More